EGF816
- CAS No.
- 1508250-71-2
- Chemical Name:
- EGF816
- Synonyms
- Nazartinib;EGF816;NVS-816;CS-1646;EGF-816;EGF 816;EGF816|||NVS-816;EGF816 Nazartinib;Nazartinib (EGF816);Nazartinib, 10 mM in DMSO;Nazartinib (EGF816, NVS-816)
- CBNumber:
- CB33040785
- Molecular Formula:
- C26H31ClN6O2
- Molecular Weight:
- 495.02
- MDL Number:
- MFCD28963918
- MOL File:
- 1508250-71-2.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Nazartinib ≥98% | 22409 | 1mg | $41 |
| Nazartinib ≥98% | 22409 | 5mg | $178 |
| Nazartinib ≥98% | 22409 | 10mg | $312 |
| Nazartinib ≥98% | 22409 | 25mg | $659 |
| Nazartinib 99.53% | CS-4325 | 5mg | $97 |
| More product size | |||
| Density | 1.28±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Store at -20°C |
| solubility | Soluble in DMSO |
| form | Powder |
| pka | 11.38±0.43(Predicted) |
| color | Off-white to yellow |
| FDA UNII | KE7K32EME8 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
EGF816 price More Price(44)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 22409 | Nazartinib ≥98% | 1508250-71-2 | 1mg | $41 | 2026-04-30 | Buy |
| Cayman Chemical | 22409 | Nazartinib ≥98% | 1508250-71-2 | 5mg | $178 | 2026-04-30 | Buy |
| Cayman Chemical | 22409 | Nazartinib ≥98% | 1508250-71-2 | 10mg | $312 | 2026-04-30 | Buy |
| Cayman Chemical | 22409 | Nazartinib ≥98% | 1508250-71-2 | 25mg | $659 | 2026-04-30 | Buy |
| ChemScene | CS-4325 | Nazartinib 99.53% | 1508250-71-2 | 5mg | $97 | 2026-06-04 | Buy |
EGF816 Chemical Properties,Uses,Production
Description
Nazartinib is an irreversible inhibitor of mutant EGF receptors (EGFRs). It is selective for EGFR mutant cell lines, including H3255 and HCC827 lung adenocarcinoma cells (IC50s = 6.11 and 1.52 nM, respectively) and resistant H1975 non-small cell lung cancer cells (NSCLC; IC50 = 4.18 nM), over cells expressing wild-type EGFRs (IC50 = 160.6 nM for HaCaT keratinocytes). Nazartinib decreases phosphorylation of EGFR in H3255, HCC827, and H1975 cells (EC50s = 5, 1, and 3 nM, respectively) and inhibits cell proliferation (EC50s = 9, 11, and 25 nM, respectively) but does not affect cell proliferation in cell lines containing wild-type EGFR. It reduces tumor growth in an HCC827 lung adenocarcinoma mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg per day for 21 days.
Uses
Nazartinib (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min1 on EGFR(L858R/790M) mutant, respectively.
in vitro
egf816 showed sustained inhibition of pegfr, which is consistent with the irreversible binding mechanism of egf816. egf816 also performs exceptionally well in long term dosing studies providing durable responses in the preclinical models [1].
in vivo
egf816 demonstrated strong in vivo tumor regressions in several egfr activating and resistant tumor models. in all of the models egf816 inhibited tumor growth dose-dependently and achieved regressions of established tumors at well tolerated doses [1].
IC 50
EGFRL858R/T790M: 31 nM (Ki)
References
[1] shailaja kasibhatla, jie li, celin tompkins, mei-ting vaillancourt, jennifer anderson, annemarie culazzo pferdekamper, chun li, oliver long, mathew mcneill, robert epple, debbie liao, eric murphy, steve bender, yong jia, gerald lelais. egf816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes t790m-mediated resistance in nsclc. [abstract]. in: proceedings of the 105th annual meeting of the american association for cancer research; 2014 apr 5-9; san diego, ca. philadelphia (pa): aacr; cancer res 2014;74(19 suppl):abstract nr 1733. doi:10.1158/1538-7445.am2014-1733
EGF816 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| career henan chemical co | +86-0371-86658258 | factory@coreychem.com | China | 29780 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 | sales@sarms4muscle.com | China | 10378 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 38999 | 58 |
| Zibo Hangyu Biotechnology Development Co., Ltd | +86-0533-2185556 +86-15965530500 | nickzhang@hangyubiotech.com | China | 9932 | 58 |
| HANGZHOU LEAP CHEM CO., LTD. | +86-571-87711850 +86-15355479329 | market18@leapchem.com | China | 43303 | 58 |
| Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 | info@fdachem.com | China | 20111 | 58 |
| Shanghai Acmec Biochemical Technology Co., Ltd. | +86-18621343501 | product@acmec-e.com | China | 33301 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 54746 | 58 |
View Lastest Price from EGF816 manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Nazartinib
1508250-71-2
|
$72.00-197.00 | 99.62% | 10g | TargetMol Chemicals Inc. | ||
 |
2020-01-09 | EGF816
1508250-71-2
|
$9.80 | 1g | ≥99% | 100kg | Career Henan Chemical Co |
-
- Nazartinib
1508250-71-2
- $72.00-197.00
- 99.62%
- TargetMol Chemicals Inc.
-
- EGF816
1508250-71-2
- $9.80
- ≥99%
- Career Henan Chemical Co
